Skip to main content

Table 2 Physical functioning outcomes of hospitalised COVID-19 survivors

From: 1-year quality of life and health-outcomes in patients hospitalised with COVID-19: a longitudinal cohort study

Outcome Timepoint 1 (N = 60) Timepoint 2 (N = 55) Timepoint 3 (N = 55) p value F value
Objective measures of recovery
 6MWTD (mean, SD) 365 (209) 421 (92) 447 (85) 0.0001 10.13
 MBS (mean, SD) 3.5 (2.4) 3.2 (2.6) 2.5 (2.4) 0.15 1.93
 Return to work n = 33
 Full employment, n (%) 13 (39) 15 (45) 18 (55) 0.32 1.17
 Reduced hours, n (%) 1 (3) 3 (9) 4 (12)   
 No return to work, n (%) 19 (58) 15 (46) 11 (33)   
 Exercise (N = 53)      
 Same exercise levels pre- and post-COVID-19, n (%) N/A 24 (45) 27 (51) 0.78 0.08
 Lower exercise levels pre- and post-COVID-19, n (%) N/A 29 (54) 26 (49)   
Falls      
 Participants reporting falls following hospital discharge, n (%) 5 (8) (between DC and T1) 4 (7) (between T1 and t = T2) 0 (between T2 and T3)   
Frailty      
 Clinical Frailty Score (median) 3 2 2   
Subjective measures of recovery
Fatigue      
 Chalder Fatigue Score (mean, SD) 17.5 (6.5) 16.7 (5.9) 16.7 (5.6) 0.73 0.32
Health-Related Quality of Life, Short-Form 36 Scores
 PF (mean, SD) 62 (24) 61 (25) 64 (25) 0.85 0.17
 rp (mean, SD) 39 (39) 50 (43) 54 (45) 0.20 1.65
 RE (mean, SD) 58 (43) 64 (41) 65 (44) 0.70 0.36
 VT (mean, SD) 47 (24) 52 (22) 49 (21) 0.50 0.70
 MH (mean, SD) 70 (23) 74 (18) 73 (19) 0.60 0.52
 SF (mean, SD) 66 (29) 76 (26) 77 (26) 0.10 2.29
 BP (mean, sd) 65 (30) 65 (27) 68 (26) 0.82 0.20
 GH (mean, SD) 61 (20) 55 (19) 54 (19) 020 1.65
 Health change (mean, sd) 44 (28) 40 (25) 61 (31) 0.0005 8.04
Patient Concerns
 Number of concerns reported (median, IRQ) 4 (7) 3 (7) 4 (7)   
 Participants reporting fatigue, n (%) 24 (40) 27 (49) 21 (38)   
 Participants reporting issues with memory/concentration, n (%) 22 (37) 19 (35) 27 (49)   
  1. Unknown or missing data: Chalder Fatigue Score: 0 (10-weeks), 1 (6-months) and 1 (12-months). 6MWTD: 0 (10-weeks), 4 (6-months) and 3 (12-months). SF-36-II: 9 (10-weeks), 2 (6-months) and 1 (12-months). Return to work: 0 (10-weeks), 0 (6-months) and 0 (12-months). Patient concerns/symptoms: 0 (10-weeks), 0 (6-months) and 1 (12-months). Exercise levels: N/A at 10-weeks, 0 (6-months) and 0 (12-months). Falls: 0 (10-weeks), 0 (6-months) and 0 (12-months)
  2. SD standard deviation, N/A not assessed, IQR interquartile range, HrQOL Health-related quality of life, PF physical function, RP role limitations due to physical problems, RE role limitations due to emotional problems, VT energy/vitality, MH emotional well-being, SF social functioning, BP bodily pain, GH general health
  3. p values are calculated for comparisons across the 3-month, 6-month and 12-month assessments using linear mixed models for continuous variables or cumulative link mixed models for ordinal variables
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us